These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 3998494

  • 1. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro.
    Cooper KD, Kang K, Chan SC, Hanifin JM.
    J Invest Dermatol; 1985 Jun; 84(6):477-82. PubMed ID: 3998494
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition.
    Chan SC, Li SH, Hanifin JM.
    J Invest Dermatol; 1993 May; 100(5):681-4. PubMed ID: 8388009
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells.
    Coqueret O, Boichot E, Lagente V.
    Clin Exp Allergy; 1997 Jul; 27(7):816-23. PubMed ID: 9249275
    [Abstract] [Full Text] [Related]

  • 6. gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition.
    Ostlere LS, Mallett RB, Kaminski A, Kaminski ER, Pereira RS, Holden CA.
    Br J Dermatol; 1995 Jul; 133(1):1-5. PubMed ID: 7669618
    [Abstract] [Full Text] [Related]

  • 7. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.
    Chan SC, Hanifin JM.
    J Lab Clin Med; 1993 Jan; 121(1):44-51. PubMed ID: 8381148
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of dexamethasone on de novo IgE synthesis by human blood lymphocytes.
    Hemady Z, Gellis S, Chambers M, Rocklin RE.
    J Allergy Clin Immunol; 1985 Feb; 75(2):304-12. PubMed ID: 3918092
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells.
    Crocker IC, Townley RG, Khan MM.
    Immunopharmacology; 1996 Mar; 31(2-3):223-35. PubMed ID: 8861748
    [Abstract] [Full Text] [Related]

  • 17. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome.
    Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER.
    Ann Allergy Asthma Immunol; 1998 Aug; 81(2):153-8. PubMed ID: 9723561
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.
    Brackeen MF, Cowan DJ, Stafford JA, Schoenen FJ, Veal JM, Domanico PL, Rose D, Strickland AB, Verghese M, Feldman PL.
    J Med Chem; 1995 Nov 24; 38(24):4848-54. PubMed ID: 7490734
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.